Background Elderly patients with atrial fibrillation are at higher risk of both ischemic and
bleeding events compared to younger patients. In a prespecified analysis from the ENGAGE …

Background Implementation of appropriate oral anticoagulant treatment for the prevention of
stroke in very elderly patients with atrial fibrillation is challenging because of concerns …

Background It is unclear whether edoxaban shows better risk reduction of ischemic stroke,
bleeding, and all-cause mortality than warfarin in Asian patients with nonvalvular atrial …

Background Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects.
The long-term efficacy and safety of edoxaban as compared with warfarin in patients with …

Background When compared with warfarin, edoxaban significantly reduced cardiovascular
mortality in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation …

Objectives To assess the risk of stroke/systemic embolism (SE) and major bleeding
associated with the use of oral anticoagulants in elderly patients with atrial fibrillation (AF) in …

Background: In the multinational, double-blind, double-dummy ENGAGE AF-TIMI 48 phase
3 study, once-daily edoxaban was non-inferior to warfarin for prevention of stroke or …

Older patients with atrial fibrillation (AF) are at higher risk of thromboembolic events and oral
anticoagulant (OAC)-related bleeding complications. This meta-analysis evaluates the …

Aims Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in
patients with atrial fibrillation (AF). Data on the safety and efficacy of edoxaban in routine …

Background: Anticoagulation is often avoided in patients with atrial fibrillation who are at an
increased risk of falling. Objectives: This study assessed the relative efficacy and safety of …